Therapeutic potential of acarbose in ameliorating the metabolic and endocrinological complications of polycystic ovarian syndrome: a review

References

• Rodgers RJ, Suturina L, Lizneva D, et al. Is polycystic ovary syndrome a 20th century phenomenon? Med Hypotheses. 2019;124:31–34. doi:10.1016/j.mehy.2019.01.019.
   PubMed Web of Science ®Google Scholar
• Deswal R, Narwal V, Dang A, et al. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261–271. Wolters Kluwer Medknow Publications; doi:10.4103/jhrs.JHRS_95_18.
   PubMedGoogle Scholar
• Jabeen A, Yamini V, Rahman Amberina A, et al. Polycystic ovarian syndrome: prevalence, predisposing factors, and awareness among adolescent and young girls of South India. Cureus. 2022;14(8):e27943. doi:10.7759/cureus.27943.
   PubMed Web of Science ®Google Scholar
• Dadachanji R, Shaikh N, Mukherjee S. Genetic variants associated with hyperandrogenemia in PCOS pathophysiology. Genet Res Int. 2018;2018:7624932. doi:10.1155/2018/7624932.
   PubMed Web of Science ®Google Scholar
• Singh S, Pal N, Shubham S, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. MDPI. 2023;12(4):1454. doi:10.3390/jcm12041454.
   PubMedGoogle Scholar
• Williams T. Diagnosis and Treatment of Polycystic Ovary Syndrome [Internet]. Am Fam Physician. 2016;94(2):106–113. Available from: http://familydoctor.org/familydoctor/en/diseases-conditions/polycystic-ovary-syndrome.html.
   Google Scholar
• Shirin Dason E, Koshkina O, Chan C, et al. Diagnosis and management of polycystic ovarian syndrome. CMAJ. 2024;196(3):E85–E94. doi:10.1503/cmaj.231251.
   PubMed Web of Science ®Google Scholar
• Sydora BC, Wilke MS, McPherson M, et al. Challenges in diagnosis and health care in polycystic ovary syndrome in Canada: a patient view to improve health care. BMC Womens Health. 2023;23:569. doi:10.1186/s12905-023-02732-2.
   Web of Science ®Google Scholar
• Tuğrul S, Kutlu T, Pekin O, et al. Clinical, endocrine, and metabolic effects of acarbose, a α-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome. Fertil Steril. 2008;90(4):1144–1148. doi:10.1016/j.fertnstert.2007.07.1326.
   PubMed Web of Science ®Google Scholar
• Ciotta L, Calogero AE, Farina M, et al. Clinical, endocrine and metabolic effects of acarbose, an α-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. Hum Reprod. 2001;16(10):2066–2072. doi:10.1093/humrep/16.10.2066.
   PubMed Web of Science ®Google Scholar
• Sönmez AS, Yasar L, Savan K, et al. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. Hum Reprod. 2005;20(1):175–179. doi:10.1093/humrep/deh580.
   PubMed Web of Science ®Google Scholar
• De Leo V, Musacchio MC, Cappelli V, et al. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. BMC 2016;14(1):38. doi:10.1186/s12958-016-0173-x.
   Google Scholar
• Dobbie LJ, Pittam B, Zhao SS, et al. Childhood, adolescent, and adulthood adiposity are associated with risk of PCOS: a Mendelian randomization study with meta-analysis. Hum Reprod. 2023;38(6):1168–1182. doi:10.1093/humrep/dead053.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome [Internet]. 2000. Annu Rev Med. 2001;52:401–419. doi:10.1146/annurev.med.52.1.401.
   Google Scholar
• Tupas GD, Otero MCB, Ebhohimen IE, et al. Antidiabetic lead compounds and targets for drug development. In: Phytochemicals as lead compounds for new drug discovery. Elsevier; 2019;127–141. doi:10.1016/b978-0-12-817890-4.00008-1
   Google Scholar
• ChemSketch. Toronto, ON, Canada: Advanced Chemistry Development, Inc. (ACD/Labs). [cited 2 May 2024].
   Google Scholar
• Joshi SR, Standl E, Tong N, et al. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opin Pharmacother. Taylor and Francis Ltd. 2015;16(13):1959–1981. doi:10.1517/14656566.2015.1070827.
   Google Scholar
• Toeller M. Modulation of intestinal glucose absorption: postponement of glucose absorption by a-glucosidase inhibitors. In: Pharmacology of diabetes: present practice and future perspectives; De Gruyter 1990;93–112. doi:10.1515/9783110850321-009
   Google Scholar
• Coniff RF, Shapiro JA, Robbins D, et al. Original reduction of glycosylated hemoglobin ana postprandial hyperglycemia by acarbose in patients with NIPPM. A placebo-controlled dose-comparison study [Internet]. Diabetes Care. 1995;8(6):817–824. doi:10.2337/diacare.18.6.817.
   Google Scholar
• Zhang YY, Hou LQ, Zhao TY. Effects of acarbose on polycystic ovary syndrome: a meta-analysis. Exp Clin Endocrinol Diabetes. 2014;122(6):373–378. doi:10.1055/s-0034-1375676.
   PubMed Web of Science ®Google Scholar
• Daneshjou D, Soleimani Mehranjani M, Zadeh Modarres S, et al. Sitagliptin/metformin: a new medical treatment in polycystic ovary syndrome. Trends Endocrinol Metab. 2020;31(12):890–892. doi:10.1016/j.tem.2020.09.002.
   PubMed Web of Science ®Google Scholar
• Mclver Lindsey A, Preuss Charles V, Jayson T. Acarbose. Treasure Island (FL): StatPearls Publishing; 2023.
   Google Scholar
• Gutzwiller JP, Göke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999;44(1):81–86. doi:10.1136/gut.44.1.81.
   PubMed Web of Science ®Google Scholar
• Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ, Calle JR, Maranes JP. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo. Diabetes Metab. 1996;22:201–202.
   PubMed Web of Science ®Google Scholar
• Hanjalic-Beck A, Gabriel B, Schaefer W, et al. Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study. Gynecol Endocrinol. 2010;26(9):690–697. doi:10.3109/09513591003686379.
   PubMed Web of Science ®Google Scholar
• Merviel P, James P, Bouée S, et al. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reprod Health. 2021;18(1):13. doi:10.1186/s12978-021-01073-3.
   PubMed Web of Science ®Google Scholar
• Afrin S, Ishrat S, Banu J, et al. Effect of aromatase inhibitor, letrozole on semen parameters in eugonadotropic hypoandrogenic men with oligozoospermia. Int J Reprod Contracept Obstet Gynecol. 2021;10(4):1272. doi:10.18203/2320-1770.ijrcog20211099.
   Google Scholar
• Vitek W, Alur S, Hoeger KM. Off-label drug use in the treatment of polycystic ovary syndrome. Fertil Steril. 2015;103(3):605–611. doi:10.1016/j.fertnstert.2015.01.019.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Deepika MLN, Supriya K, et al. CYP11A1 microsatellite (tttta)n polymorphism in PCOS women from South India. J Assist Reprod Genet. 2014;31(7):857–863. doi:10.1007/s10815-014-0236-x.
   PubMed Web of Science ®Google Scholar
• Snehalatha C, Viswanathan V, Ramachandran A. Cutoff values for normal anthropometric variables in Asian Indian adults [internet]. Diabetes Care. 2003;26(5):1380–1384. doi:10.2337/diacare.26.5.1380.
   PubMed Web of Science ®Google Scholar
• van Keizerswaard J, Dietz de Loos ALP, Louwers YV, et al. Changes in individual polycystic ovary syndrome phenotypical characteristics over time: a long-term follow-up study. Fertil Steril. 2022;117:1059–1066. doi:10.1016/j.fertnstert.2022.01.014.
   PubMed Web of Science ®Google Scholar
• Barber TM, McCarthy MI, Wass JAH, et al. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2006;65(2):137–145. doi:10.1111/j.1365-2265.2006.02587.x
   PubMedGoogle Scholar
• Khan MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): current perspectives. Application of Clinical Genetics. Dove Medical Press Ltd.; 2019;(12):249–260. doi:10.2147/TACG.S200341.
   Google Scholar
• Teede H, Deeks A, Moran L. Open access review polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan [internet]. BMC Med. 2010;8(1):41. doi:10.1186/1741-7015-8-41.
   PubMed Web of Science ®Google Scholar
• Louwers YV, Laven JSE. Characteristics of polycystic ovary syndrome throughout life. Ther Adv Reprod Health. 2020;14:2633494120911038. doi:10.1177/2633494120911038.
   Google Scholar
• Bulsara J, Patel P, Soni A, et al. A review: brief insight into polycystic ovarian syndrome. Endocrine and Metabolic Sci. Elsevier Ltd. 2021;3:100085. doi:10.1016/j.endmts.2021.100085.
   Google Scholar
• Barr S, Hart K, Reeves S, et al. Habitual dietary intake, eating pattern and physical activity of women with polycystic ovary syndrome. Eur J Clin Nutr. 2011;65(10):1126–1132. doi:10.1038/ejcn.2011.81.
   PubMed Web of Science ®Google Scholar
• Krug I, Giles S, Paganini C. Binge eating in patients with polycystic ovary syndrome: prevalence, causes, and management strategies. Neuropsychiatr Dis Treat. Dove Medical Press Ltd; 2019;15:1273–1285. doi:10.2147/NDT.S168944.
   Google Scholar
• WHO expert consultation. WHO BMI values. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–163. doi:10.1016/S0140-6736(03)15268-3.
   Google Scholar
• Penna IAA, Canella PRB, Reis RM, et al. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod. 2005;20(9):2396–2401. doi:10.1093/humrep/dei104.
   PubMed Web of Science ®Google Scholar
• Lashen H. Review: role of metformin in the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2010;1(3):117–128. doi:10.1177/2042018810380215.
   Google Scholar
• Shaikh N, Dadachanji R, Mukherjee S. Genetic markers of polycystic ovary syndrome: emphasis on insulin resistance. Int J Med Gen. 2014;2014:1–10. doi:10.1155/2014/478972.
   Google Scholar
• Barber TM, Franksb S. Genetics of polycystic ovary syndrome. In: Polycystic ovary syndrome: novel insights into causes and therapy. Front Horm Res. 2012;40:28–39. doi:10.1159/000341682.
   Google Scholar
• Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women*. J Clin Endocrinol Metabolism Printed. 1999;84(1):165–169. doi:10.1210/jc.84.1.165.
   PubMed Web of Science ®Google Scholar
• Ehrmann D. Glucose intolerance in PCOS. Diabetes Care 1999;22(1):141–146. doi:10.2337/diacare.22.1.141.
   Google Scholar
• O’mearat NM, Blackman? JD, Ehrmann DA, et al. Defects in, &cell function in functional ovarian hyperandrogenism*. J Clin Endocrinol Metabol 1993;76(5):1241–1247. doi:10.1210/jcem.76.5.8496316.
   PubMed Web of Science ®Google Scholar
• Van de Laar FA, Lucassen PLBJ, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(2):CD003639. doi:10.1002/14651858.CD003639.pub2.
   Google Scholar
• Krook A, Kumar S, Laing I, et al. Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes. 43(3):357–368. doi:10.2337/diab.43.3.357.
   PubMed Web of Science ®Google Scholar
• Chou C-W, Ou H-Y, Hsiao S-H, et al. Differential responses to acarbose between obese and non-obese patients with type 2 diabetes mellitus. Int J Endocrinol Metab. 2006;4(2):63–69.
   Google Scholar
• Rachmani R, Bar-Dayan Y, Ronen Z, et al. The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study. Diabetes Obes Metab. 2004;6(1):63–68. doi:10.1111/j.1463-1326.2004.00317.x.
   Google Scholar
• Araujo Penna I, Canella PRB, Vieira CS, et al. Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome. Fertil Steril. 2007;88(2):519–522. doi:10.1016/j.fertnstert.2006.11.073.
   PubMed Web of Science ®Google Scholar
• Geisthövel F, Frorath B, Brabant G. Acarbose reduces elevated testosterone serum concentrations in hyperinsulinaemic premenopausal women: a pilot study* [internet]. Hum Reprod. 1996;11(11):2377–2381. doi:10.1093/oxfordjournals.humrep.a019118.
   PubMed Web of Science ®Google Scholar
• Rezai M, Jamshidi M, Mohammadbeigi R, et al. Comparing the effect of metformin and acarbose accompanying clomiphene on the successful ovulation induction in infertile women with polycystic ovary syndrome. Glob J Health Sci. 2016;8(9):54516. doi:10.5539/gjhs.v8n9p281.
   PubMedGoogle Scholar
• Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12–22. doi:10.1172/JCI77812.
   PubMed Web of Science ®Google Scholar
• Masuda S, Fujishima Y, Maeda N, et al. Impact of glycosylphosphatidylinositol-specific phospholipase D on hepatic diacylglycerol accumulation, steatosis, and insulin resistance in diet-induced obesity. Am J Physiol Endocrinol Metab. 2019;316(2):E239–E250. doi:10.1152/ajpendo.00319.2018.
   PubMed Web of Science ®Google Scholar
• Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565–4592. doi:10.1210/jc.2013-2350.
   PubMed Web of Science ®Google Scholar
• Salley KES, Wickham EP, Cheang KI, et al. Position statement: glucose intolerance in polycystic ovary syndrome - A position statement of the androgen excess society. J Clin Endocrinol Metab. 2007;92(12):4546–4556. doi:10.1210/jc.2007-1549.
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Practice Bulletins—Gynecology. acog-practice-bulletin-no-108-polycystic-ovary-syndrome-2009. Obstet Gynecol. 2009;114(4):936. doi:10.1097/AOG.0b013e3181bd12cb.
   Google Scholar
• Kim H, Kadowaki H, Sakura H, et al. Detection of mutations in the insulin receptor gene in patients with insulin resistance by analysis of single-stranded conformational polymorphisms. Diabetologia. 1992;35(3):261–266. doi:10.1007/BF00400927.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Haffner SM, Menschikowski M, et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes [internet]. Diabetes Res Clin Pract. 2002;55(3):221–227. doi:10.1016/s0168-8227(01)00347-3.
   PubMed Web of Science ®Google Scholar
• Qiao W, Li J, Li Y, et al. Acarbose, the α-glucosidase inhibitor, attenuates the blood pressure and splanchnic blood flow responses to meal in elderly patients with postprandial hypotension concomitant with abnormal glucose metabolism. Blood Press Monit. 2016;21(1):38–42. doi:10.1097/MBP.0000000000000160.
   PubMed Web of Science ®Google Scholar
• Chiasson J, Josse RG, Lawrence Leiter FA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care. 1996;19(11):1190–1193. doi:10.2337/diacare.19.11.1190.
   Google Scholar
• Joham AE, Boyle JA, Zoungas S, et al. Hypertension in reproductive-aged women with polycystic ovary syndrome and association with obesity. Am J Hypertens. 2015;28(7):847–851. doi:10.1093/ajh/hpu251.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Rubin KH, Nybo M, et al. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol. 2018;17(1):37. doi:10.1186/s12933-018-0680-5.
   PubMedGoogle Scholar
• Raperport C, Homburg R. The source of polycystic ovarian syndrome. Clin Med Insights Reprod Health. 2019;13:1179558119871467. doi:10.1177/1179558119871467.
   Web of Science ®Google Scholar
• Yousefi M, Fateh ST, Nikbaf-Shandiz M, et al. The effect of acarbose on lipid profiles in adults: a systematic review and meta-analysis of randomized clinical trials. BMC Pharmacol Toxicol. 2023;24(1):65. doi:10.1186/s40360-023-00706-6.
   PubMed Web of Science ®Google Scholar
• Hu D, Guo Y, Wu R, et al. New insight into Metformin-induced cholesterol-lowering effect crosstalk between glucose and cholesterol homeostasis via ChREBP (carbohydrate-responsive element-binding protein)-mediated PCSK9 (proprotein convertase subtilisin/kexin type 9) regulation. Arterioscler Thromb Vasc Biol. 2021;41:E208–E223. doi:10.1161/ATVBAHA.120.315708.
   PubMed Web of Science ®Google Scholar
• Bu X, Wang X, Lin Z, et al. Myo-inositol improves growth performance and regulates lipid metabolism of juvenile Chinese mitten crab (Eriocheir sinensis) fed different percentage of lipid. Br J Nutr. 2022;127(5):666–678. doi:10.1017/S0007114521001409.
   PubMed Web of Science ®Google Scholar
• Osonoi T, Saito M, Mochizuki K, et al. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus. Metabolism. 2010;59(12):1816–1822. doi:10.1016/j.metabol.2010.06.006.
   PubMed Web of Science ®Google Scholar
• Rosenthal JH, Mauersberger H. Effects on blood pressure of the α-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Investig. 2002;22(10):695–701. doi:10.2165/00044011-200222100-00006.
   Google Scholar
• Panda PK, Rane R, Ravichandran R, et al. Genetics of PCOS: a systematic bioinformatics approach to unveil the proteins responsible for PCOS. Genom Data. 2016;8:52–60. doi:10.1016/j.gdata.2016.03.008.
   PubMedGoogle Scholar
• Soldat-Stanković V, Popović-Pejičić S, Stanković S, et al. The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. J Endocrinol Invest. 2022;45(3):583–595. doi:10.1007/s40618-021-01691-5.
   PubMed Web of Science ®Google Scholar
• Unfer V, Russo M, Aragona C, et al. Treatment with Myo-Inositol does not improve the clinical features in all PCOS phenotypes. Biomedicines. 2023;11(6):11. doi:10.3390/biomedicines11061759.
   Web of Science ®Google Scholar
• Ajmal N, Khan SZ, Shaikh R. Polycystic ovary syndrome (PCOS) and genetic predisposition: a review article. Eur J Obstet Gynecol Reprod Biol X. 2019;3:100060. doi:10.1016/j.eurox.2019.100060.
   PubMedGoogle Scholar